TaiRx, Inc. (6580.TWO) stock: key figures, P/E, revenue and dividend

Health Care · Taiwan · ISIN TW0006580004

Price
11.90 TWD
Market cap
1.33 bn TWD
P/E (2025)
–
P/S (2025)
47.86
Dividend yield
0.00 %
Net margin
-793.28 %
Return on equity (ROE)
-50.08 %
Return on assets (ROA)
-47.53 %

TaiRx, Inc. financials

Fiscal year20242025
Revenue8.22 m TWD27.88 m TWD
Gross profit1.34 m TWD10.09 m TWD
Operating income-145.96 m TWD-237.36 m TWD
EBIT-138.56 m TWD-222.28 m TWD
Net income-138.84 m TWD-221.13 m TWD
Diluted EPS – continuing operations-1.26 TWD-1.97 TWD

Full history since 2019, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About TaiRx, Inc.

TaiRx, Inc. focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases. The company's products under development include CVM-1118, an oral anti-cancer drug that is Phase II clinical trial. Its pre-clinical products comprise TRX-920, an oral delivery formulation; and TRX-105, a molecule developed for treating and alleviating symptoms of various colitis. The company also offers Zelnite, a drug that helps in treatment of selenium deficiency; and focuses on development of the nodal diagnostic devices and anti-body drugs for the use in cancer therapy. TaiRx, Inc. was founded in 2011 and is based in Taipei, Taiwan.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.